X hits on this document





17 / 18

  • 22.

    Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2006;91(6):1995-2010.

  • 23.

    Morales A, Tenover JL. Androgen deficiency in the aging male: when, who, and how to investigate and treat. Urol Clin North Am. 2002;29(4):975-982, x.

  • 24.

    AACE Hypogonadism Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients— 2002 update. Endocr Pract. 2002;8(6):439-456.

  • 25.

    Gurbuz N, Mammadov E, Usta MF. Hypogonadism and erectile dysfunction: an overview [review]. Asian J Androl. 2008;10(1):36-43.

  • 26.

    Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Utility, limitations, and pitfalls in measure testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab. 2007;92(2):405-413.

  • 27.

    Wang C, Catlin DH, Demers LM, Starcevic B, Swerdloff RS. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography- tandem mass spectrometry. J Clin Endocrinol Metab. 2004;89(2):534-543.

  • 28.

    Lazarou S, Reyes-Vallejo L, Morgentaler A. Wide variability in laboratory reference values for serum testosterone. J Sex Med. 2006;3(6):1085-1089.

  • 29.

    Hormone standardization. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/nceh/dls/hormone_standardization.htm. Accessed July 30, 2008.

  • 30.

    Free and bioavailable testosterone calculator. International Society for the Study of the Aging Male Web site. http://issam.ch/freetesto.htm. Accessed August 5, 2008.

  • 31.

    Nieschlag E, Swerdloff R, Behre HM, et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. J Androl. 2006;27(2):135-137.

  • 32.

    Zitzmann M. Mechanisms of disease: pharmacogenetics of testosterone therapy in hypogonadal men [review]. Nat Clin Pract Urol. 2007;4(3):161-166.

  • 33.

    Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab. 2006;91(11):4335-4343.

34. Vermeulen A. Androgen replacement therapy in the aging male—a critical evaluation. J Clin Endrocrinol Metab. 2001;86(6):2380-2390.


  • 35.

    Dean JD, Carnegie C, Rodzvilla J Jr, Smith T. Long-term effects of Testim® 1% testosterone gel in hypogonadal men. Rev Urol. 2004;6(suppl 6):S22-S29.

  • 36.

    Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154(6):899-906.

  • 37.

    Liu PY, Yee B, Wishart SM, et al. The short-term effects of high-dose testosterone on sleep, breathing, and function in older men. J Clin Endocrinol Metab. 2003;88(8):3605-3613.

  • 38.

    Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta- analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005;60(11):1451-1457.

  • 39.

    Huggins C, Hodges CV. Studies on prostatic cancer, I: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293-297. Reprinted by: J Urol. 2002;167(2 Pt 2):948-951.

  • 40.

    Morgentaler A. Testosterone replacement therapy and prostate cancer. Urol Clin North Am. 2007;34(4):555-563, vii.

  • 41.

    Morgentaler A, Rhoden EL. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology. 2006;68(6):1263-1267.

  • 42.

    Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone does- response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001;281(6):E1172-E1181.

  • 43.

    Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level 4.0 ng per milliliter. N Engl J Med. 2004;350(22):2239-2246.

  • 44.

    Marks LS, Mazer NA, Mostaghel E, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006;296(19):2351-2361.

  • 45.

    Endogenous Hormones and Prostate Cancer Collaborative Group. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008;100(3):170-183.

  • 46.

    Von Eckardstein S, Nieschlag E. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. J Androl. 2002;23(3):419-425.

Document info
Document views58
Page views58
Page last viewedTue Jan 17 05:58:24 UTC 2017